Sectors We Support
hVIVO accelerates drug development for start-ups, biotechs, CROs, and pharma
hVIVO supports organisations across the entire drug development ecosystem — from early‑stage start‑ups and scaling biotechs to global pharmaceutical companies and CRO partners. With 30–40 years of early‑phase and challenge trial expertise, GCP/GCLP‑compliant labs, specialist populations, and owned clinical sites, we deliver predictable timelines, scientific depth, and operational excellence. Our integrated model brings together scientific consulting, assay development, modelling, regulatory strategy, early clinical execution, and infectious disease challenge capabilities to accelerate progress, reduce risk, and generate high‑quality data for key decision points.
- 35+ years of early development experience and expertise
- Integrated scientific, clinical, regulatory & laboratory ecosystem
- Owned clinical sites enabling predictable timelines and capacity
- Proven acceleration of early‑phase and challenge studies
- Trusted by global pharma, high‑growth biotechs & emerging start‑ups
Contact Us
Discover More
Biotech
Integrated ecosystem for assay development, biomarkers, modelling, early clinical and regulatory planning.
Pharmaceutical
Predictable early‑phase delivery, owned sites, specialist cohorts, human challenge expertise.
CROs
Specialist early-phase, and challenge units, laboratory, and special population capabilities that expand CRO capacity.
FAQs
hVIVO supports the full drug‑development ecosystem — including early‑stage start‑ups, scaling biotechs, global pharmaceutical companies and CRO partners .
Our integrated ecosystem brings together scientific consulting, assay development, laboratory services, modelling, regulatory strategy, early clinical execution and human challenge trial expertise to deliver predictable timelines and high‑quality data for key decision points.
Each sector faces growing complexity, resource pressure and the need for reliable, defensible early‑phase data. hVIVO’s model provides senior scientific expertise, specialised clinical populations, owned clinical sites and operational excellence to address these challenges.
Contact Our Team
Submit your RFI/RFP Request